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1607-551X/Copyright ª 2014, KaohsiuAbstract Oral squamous cell carcinoma can be preceded by some benign oral lesions with ma-
lignant potential, including leukoplakia, erythroplakia, oral lichen planus, and oral submucous
fibrosis. There are different degrees of inflammatory cells infiltration in histopathology. Inflam-
matory cytokines may play a pathogenic role in the development of oral precancerous lesions
(OPCLs). Genetic polymorphisms of cytokine-encoding genes are known to predispose to malig-
nant disease. We hypothesized that the risk of OPCLs might be associated with cytokine gene
polymorphisms of interferon (IFN)-g, transforming growth factor (TGF)-b1, tumor necrosis factor
(TNF)-a, interleukin (IL)-6, and IL-10. In the present study, 42 OPCL patients and 128 controls
were analyzed for eight polymorphisms in five different cytokine genes [IFN-g (þ874 T/A),
TGF-b1 (codons 10 T/C and 25 G/C), TNF-a (308 G/A), IL-6 (174 G/C), and IL-10 (1082
A/G, e819 T/C, and 592 A/C)]. Cytokine genotyping was determined by the polymerase chain
reaction sequence-specific primer technique using commercial primers. Allele and genotype
data were analyzed for significance of differences between cases and controls using the Chi-
square (c2) test. Two-sided p < 0.05 were considered to be statistically significant. A series of
multivariate logistic regression models, adjusted for age, sex, betel quid chewing, alcoholeclare no conflicts of interest.
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552 H.-J. Hsu et al.consumption, and smoking,was constructed in order to access the contribution of homozygous or
heterozygous variant genotypes of polymorphisms. The TNF-a (308) polymorphism was signif-
icantly associated with OPCLs. There were significant differences in the distribution of AA, GA,
and GG genotypes between OPCL patients and controls (pZ 0.0004). Patients with the AA or
GAgenotype hada3.63-fold increased risk ofOPCLs. TheTGF-b1 (codon 10and25) polymorphism
was also significantly associatedwith OPCLs (p< 0.001). The IL-6 polymorphismwas significantly
associatedwith OPCLs. There are significant differences in the distribution of CC, GC, andGG ge-
notypes between OPCL patients and controls (p < 0.001). Patients with the CC or GC genotype
had a 35- or 20.59-fold increased risk of OPCLs. There were no significant differences in the dis-
tribution of IL-10 and IFN-g genotypes between different groups of control individuals and OPCL
patients. The IL-6, TGF-b1, and TNF-a gene polymorphisms may have a significant association
with the development of OPCLs.
Copyright ª 2014, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Oral squamous cell carcinoma is the eighth most common
cancer in the world, with approximately 300,000 new cases
diagnosed annually. In Taiwan, this disease is the fourth
leading cause of cancer-related deaths in males. Oral squa-
mous cell carcinoma can be preceded by some benign oral
lesions with malignant potential, such as leukoplakia,
erythroplakia, oral lichen planus, and oral submucous
fibrosis. There are chronic inflammatory and immunologic
processes. Although the most common oral premalignant
lesions appear to be related to the habit of chewing betel
quid, tobacco smoking, and heavy alcohol consumption, the
shift in the balance between pro- and anti-inflammatory cy-
tokines may affect the inflammation-mediated oncogenesis.
Cytokines are important mediators of inflammatory re-
sponses. They may either be involved in the antitumor
effector immune mechanisms or may enhance malignant
transformation and tumor growth. Th1 type cytokines such
as interferon (IFN)-g are required for antitumor immunity,
whereas Th2 type and several inflammatory cytokines such
as tumor necrosis factor (TNF)-a and transforming growth
factor (TGF)-b1 favor tumor development [1]. Interleukin
(IL)-6, another cytokine of Th2 type, plays an important
role in different physiologic and pathophysiologic processes
such as inflammation, bone metabolism, and carcinogenesis
[2]. In a previous study, we found that there were different
releasing of cytokines using arecoline cultured peripheral
blood mononuclear cells from patients with oral mucous
diseases and controls [3].
Single nucleotide polymorphisms (SNPs) in genes
encoding for susceptibility factors may influence gene
expression, protein function, and disease predisposition.
An increasing number of recent reports suggested that
SNPs in cytokine genes, such as TNF-a (308), TGF-b1
(codons 10 and 25), IL-10 (1082, 819, and 592), IL-6
(174), and IFN-g (þ874), have been correlated with an
increased risk for developing oral malignancies [4e6].
However, reports discussing about the association of
cytokine polymorphism and oral precancerous lesion are
limited. The aim of this study was to determine any
possible gene polymorphisms of TNF-a (308), TGF-b1
(codons 10 and 25), IL-10 (1082, 819, and 592), IL-6(174), and IFN-g (þ874) that may influence any suscep-
tibility to oral precancerous lesions.Materials and methods
Recruitment of study participants
Of the study participants, the oral precancerous lesion
(OPL) patients were recruited between April 2004 and
November 2006 and control individuals between March 2006
and September 2006; informed consent was obtained from
all participants prior to being enrolled in the study. A total
of 42 patients were treated at the Department of Oral and
Maxillofacial Surgery of Chung-Ho Memorial Hospital,
Kaohsiung Medical University in Kaohsiung, Taiwan. The
healthy control group comprised 128 consecutive volun-
teers who attended the yearly health check-up. All patients
were diagnosed histologically by incisional biopsy or surgi-
cal specimen. After obtaining written informed consent,
10 mL of peripheral blood was collected for DNA extraction.
Each participant was interviewed using a standard ques-
tionnaire by a trained nurse, to collect medical histories,
demographic characteristics, and information on the his-
tory of exposure to risk factors such as betel quid chewing,
cigarette smoking, and alcohol consumption. The experi-
mental protocol was approved by the Institutional Review
Board of Kaohsiung Medical University Hospital.
DNA isolation and cytokine genotyping
Genomic DNA was extracted from whole EDTA-treated pe-
ripheral blood using a QIAamp Blood Kit (Qiagen, Hilden,
Germany), according to the manufacturer’s instructions.
SNPs were analyzed in five cytokines (IFN-g, TGF-b1, TNF-a,
IL-6, and IL-10) for genotype assignment. A coding sequence
mutation (G vs. C) at position 174 of the promoter region
was analyzed for the IL-6 (174, rs1800795). Three different
polymorphisms were examined for the IL-10 promoter re-
gion: positions 1082 (G vs. A, rs1800896), 819 (C vs. T,
rs1800871), and592 (A vs. C, rs1800872). The presence of a
single nucleotide modification at position þ874 (rs2430561)
was examined for IFN-g. Two single nucleotide mutations in
Table 1 Characteristics of the study population.
Variable Cases (n Z 42) Controls (n Z 128) p
Age (y)
55 28 (67) 49 (38.3) 0.0013*
>55 14 (33) 79 (61.7)
Sex
Male 9 (21.4) 77 (60.2) <0.0001*
Female 33 (78.6) 51 (39.8)
Betel quid chewing status
Ever 11 (26.2) 22 (17.2) 0.2118
Never 31 (73.8) 106 (82.8)
Alcohol drinking consumption status
Ever 13 (31) 32 (25) 0.4530
Never 29 (69) 96 (75)
Smoking status
Ever 13 (31) 38 (29.7) 0.2118
Never 29 (69) 90 (70.3)
Data are presented as n (%).
* Statistically significant difference between patients and con-
trol individuals (p < 0.05).
Table 2 Diagnosis of oral mucosa disease.
Diagnosis Number
Epithelium hyperplasia and epithelium
dysplasia
2
Epithelium hyperplasia 1
Hyperorthokeratosis 3
Hyperparakeratosis 5
Hyperparakeratosis and epithelium
dysplasia
2
Hyperorthokeratosis and oral
submucous fibrosis
3
Oral submucous fibrosis 2
Verrucous hyperplasia 2
Verrucous hyperplasia and epithelium
dysplasia
1
Verrucous hyperplasia and oral
submucous fibrosis
1
Verrucous hyperplasia, oral submucous
fibrosis, and epithelium dysplasia
2
Lichen planus 18
Total 42
Polymorphisms of cytokine gene and risk of OPL 553the coding regionwere analyzed for TGF-b1: codon 10 can be
either T or C (rs1982073), and codon 25 (1800471) can be
either C or G. SNPs at position 308 of the promoter region
(either A or C or both, rs1800629) were surveyed for TNF-a.
Cytokine genotypes were determined using the polymerase
chain reaction sequence-specific primermethodemploying a
commercially available kit (One Lambda, Inc., Canoga Park,
CA,USA) in accordancewith themanufacturer’s instructions.
All polymerase chain reaction products were visualized after
electrophoresis on a 2% agarose gel and ethidium bromide
staging. DNA extractions and polymerase chain reaction
amplificationswereperformedby a technician blinded to the
study groups.
Statistical analysis
Statistical analysiswas conductedusing JMP software version
9 (SAS Institute Inc., Cary, NC, USA) for Microsoft Windows.
The Pearson c2 test or Fisher’s exact test was used to analyze
the difference in frequencies between two or more groups.
HardyeWeinberg equilibriumwas tested using the goodness-
of-fit c2 test to compare the observed genotype frequencies
with the expected ones in the healthy controls. To determine
whether an association existed between cytokine genotypes
and allele frequencies associated with cancer risk, the sig-
nificance of the difference in the distribution of genotypes
and alleles between patients and control individuals was
calculated by c2 statistics or Fisher’s exact test and shown by
p values. All p values were two sided. A p value of< 0.05 was
considered statistically significant. To control the potential
confounding effects (age, smoking, drinking, and betel quid
chewing status), logistic regression was used to adjust for
possible confounders and to test for associations between
predictors and outcomes for odds ratio (OR) and 95% confi-
dence interval (CI).
Results
Table 1 presents clinical characteristics of the study par-
ticipants. Although there were differences in the age
group, sex distribution, betel quid chewing habit, drinking
habit, and smoking habit between the cases and controls,
these were taken into consideration during the computa-
tion of ORs to compare between genotype. The age range
of the patients with OPL was 26e79 years, with a median
age of 50.83 years and a 95% CI of 36.69e63.97 years. The
respective age range of the healthy controls was 23e83
years, with a median age of 59.20 years and a 95% CI of
46.29e72.11 years. Table 2 presents the histological diag-
nosis of OPLs. We included the patient with OPL among
leukoplakia, erythroplakia, oral lichen planus, and oral
submucous fibrosis. Genotype distribution of the controls
satisfied the HardyeWeinberg equilibrium.
Allele frequency and genotype distribution
Allele frequencies and genotype distributions of IL-6, IL-10,
IFN-g, TGF-b1, and TNF-a are shown in Tables 3 and 4.
SNP analysis for TNF-a (308) position revealed that the
“G” allele was more common than the “A” allele in both the
OPL and the control groups. Frequencies of the allele “G”(0.75 vs. 0.63, pZ 0.0433) and of the homozygous form (G/
G) were found to be significantly higher in the healthy
control individuals compared to those in OPL patients
(51.6% vs. 26.2%, pZ 0.0004; Table 3). Moreover, as shown
in Table 5, the high-producing genotypes (G/A and A/A)
were found much more commonly among the OPL patients
in comparison to low-producing ones (OR Z 3.63, 95% CI
1.65e7.97, p < 0.001).
Frequency of the T allele in the OPL patient population
(46.4%) was not different from that in the control group
(50.0%) in TGF-b1 codon 10 (Table 3). Genotype frequencies
(TT, TC, and CC) at codon 10 among both the OPL patients
and the healthy controls showed similar distribution.
Table 3 Distribution and allele frequency of TNF-a (308), TGF-b1 (codon 10 and 25), IL-10 (1082, 819, 592), IL-6 (174),
IFN-g (þ874) among BOMDP and healthy controls.
Cytokine gene Genotype
frequency (%)
BOMDP Controls p Adjusted OR
(age, sex, habits)
95% CI p
TNF-a (308)a AA 1 (2.4) 10 (7.8) <0.001* n.s.
GA 28 (66.7) 38 (29.7) 4.03 (1.61, 10.73) 0.0026*
GG 11 (26.2) 66 (51.6) 1.00
A 30 (37.5) 58 (25.4) 0.0433* n.s.
G 50 (62.5) 170 (74.6)
TGF-b1 (codon 10)
TT 1 (2.4) 8 (6.3)
TC 37 (88.1) 113 (88.3) n.s.
CC 4 (9.5) 3 (2.34)
T 39 (46.4) 129 (50.0) n.s.
C 45 (53.6) 119 (48.0)
TGF-b1 (codon 25)
CC 0 (0) 1 (0.8) <0.001* Unstable
GC 17 (40.5) 8 (6.5) 23.00 (6.16, 113.23) <0.001*
GG 25 (59.5) 115 (92.7) 1.00
C 17 (20.2) 10 (4.3) <0.001* 12.10 (3.96, 41.74) <0.001*
G 67 (79.8) 238 (96.7) 1.00
IL-10 (1082)b
GG 0 (0) 0 (0)
GA 4 (11.8) 16 (14.3) n.s.
AA 30 (88.2) 96 (85.7)
G 4 (5.9) 16 (7.1) n.s.
A 64 (94.1) 208 (92.9)
IL-10 (819)b
TT 10 (29.4) 53 (47.3)
CT 22 (64.7) 51 (45.5) n.s.
CC 2 (5.9) 8 (7.1)
T 42 (61.8) 157 (70.1) n.s.
C 26 (38.2) 67 (29.9)
IL-10 (592)b
AA 10 (29.4) 53 (47.3)
CA 22 (64.7) 51 (45.5) n.s.
CC 2 (5.9) 8 (7.1)
A 42 (61.8) 157 (70.1) n.s.
C 26 (38.2) 67 (29.9)
IL-6 (174)a
CC 5 (11.9) 4 (3.70) <0.0001* 35.00 (5.28, 266.90) <0.001*
GC 30 (71.4) 26 (24.0) 20.59 (6.44, 81.73) <0.001*
GG 5 (11.9) 78 (72.2) 1.00
C 40 (50) 34 (15.7) <0.0001* 5.05 (2.49, 10.72) <0.001*
G 40 (50) 182 (84.3) 1.00
IFN-g (þ874)c
AA 28 (66.7) 81 (63.3) n.s.
TA 11 (26.2) 35 (27.3)
TT 0 (0) 5 (3.90)
A 67 (85.9) 197 (81.4) n.s.
T 11 (14.1) 45 (18.6)
Data are presented as n (%).
BOMDP Z benign oral mucosa disease patients; CI Z confidence interval; IFN Z interferon; IL Z interleukin; n.s. Z not statistically
significant (p > 0.05); OR Z odds ratio; TGF Z transforming growth factor; TNF Z tumor necrosis factor.
* Statistically significant difference between patients and control individuals (p < 0.05).
a Due to some technical problems, the genotyping results of 40 patients were included.
b Due to some technical problems, the genotyping results of 34 patients were included.
c Due to some technical problems, the genotyping results of 39 patients were included.
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Table 4 Distributions of combined polymorphisms at
different positions of TGF-b1 and IL-10.
Cytokine gene
polymorphisms
Patients, n (%) Controls, n (%) p*
TGF-b1 (codon 10 and 25)
T/T-G/G 1 (2.4) 7 (5.7) <0.001*
T/C-G/G 22 (52.4) 106 (85.5)
T/C-G/C 15 (35.7) 7 (5.7)
C/C-G/G 2 (4.8) 2 (1.6)
T/T-G/C 0 (0.0) 0 (0.0)
C/C-G/C 2 (4.8) 1 (0.8)
C/C-C/C 0 (0.0) 0 (0.0)
T/T-C/C 0 (0.0) 1 (0.8)
T/C-C/C 0 (0.0) 0 (0.0)
IL-10 (1082, 819, 592)a
GCC/GCC 0 (0.0) 0 (0.0)
GCC/ACC 0 (0.0) 5 (4.5)
GCC/ATA 4 (11.8) 11 (9.8)
ACC/ACC 2 (5.9) 3 (2.7) n.s.
ACC/ATA 18 (52.9) 40 (35.7)
ATA/ATA 10 (29.4) 53 (47.3)
ACA/ATA 0 (0.0) 0 (0.0)
ATC/ATA 0 (0.0) 0 (0.0)
GCC/ATC 0 (0.0) 0 (0.0)
* Statistically significant difference between patients and con-
trol individuals (p < 0.05).
IL Z interleukin; n.s. Z not statistically significant (p > 0.05);
TGF Z transforming growth factor.
a Due to some technical problems, the genotyping results of
34 patients were included.
Polymorphisms of cytokine gene and risk of OPL 555Fifty-nine percent (25/42) of OPL patients and 92.7% of the
healthy controls had the high-producer GG genotype at
codon 25 (Table 3). The intermediate-producer GC geno-
type was present in 40.5% (17/42) of the OPL patients, and
in 6.5% (8/124) of the healthy controls. Only one in the
control group and none of the OPL patients had the low-
producer CC (Pro/Pro) genotype. In case of the high-
producer G (Arg) allele, the percentages of OPL patients
(79.8%) and controls (96.0%) were different (p < 0.0001).
The respective frequencies of the C allele were 23.4% for
patients with oral squamous cell carcinoma, 20.2% for pa-
tients with OPL, and 4.3% for the healthy controls. There
was a difference in the polymorphism at codon 25 of TGF-
b1 gene between patients and controls (p < 0.0001). People
with TGF-b1 codon 25 C-allele containing genotypes (GC or
CC) posed an increased risk of OPL (adjusted OR Z 23.0,
95% CI Z 6.16e113.23, p < 0.0001). The different geno-
types of TGF-b1 in codon 10e25 are associated with the
production of different cytokines. High-production geno-
types are TTGG and TCGG; intermediate-production geno-
types TCGC, TTGC, and CCGG; and low-production
genotypes TTCC and CCGC. The group of intermediate- and
low-production genotypes were significantly higher in the
patient group than those in the control group (OPL
patients:controls Z 45.2%:11.72%, p < 0.001). People with
intermediate- or low-production genotypes posed an
increased risk of OPL (adjusted OR Z 13.40, 95%
CI Z 3.81e56.66, p < 0.0001).Of the OPL patients, 12.5% (5/40) and 72.2% of the
healthy controls had the high-producer GG (Arg/Arg) ge-
notype at IL-6 e174 gene (Table 3). The high-producer GC
(Arg/Pro) genotype was present in 75.00% (30/40) of the
OPL patients, and 24.1% (26/108) of the healthy controls.
Only four in the control group had the low-producer CC
(Pro/Pro) genotype. There was a difference in the poly-
morphism at IL-6 174 gene between patients and controls
(p < 0.0001). In case of the high-producer G (Arg) allele,
the percentages of OPL patients (50.00%) and controls
(84.3%) were different (p < 0.0001). The respective fre-
quencies of the C allele were 50.00% for the patients with
OPL and 15.74% for the healthy controls. People with
IL-6 174 C-allele containing genotypes (GC or CC) posed
an increased risk of OPL (GC/GG: adjusted OR Z 20.6, 95%
CI Z 6.44e81.73, p < 0.0001; CC/GG: adjusted OR Z 35,
95% CI Z 5.28e266.90, p < 0.0001) (Table 3).
Allele and genotype frequencies of the OPL patients in
IL-10 (1082, 819, and 592) and IFN-g (þ874) showed a
similar distribution pattern to that in the healthy control
individuals (Tables 3e5).Discussion
In the present study, we found that functional poly-
morphisms at TNF-a 308 G > A, TGF-b1 codon 25 G > C,
and IL-6 174 G > C have significant effects on the risk of
OPL development. The female patients were more than
males in the study because the blood examination doesn’t
be involved in the routine protocol of treatment of the oral
precancerous lesions and female patients were more willing
to join the study. We assume that there is no difference
between females and males regarding the distribution of
polymorphisms of those cytokines.
Expressions of these cytokines in different poly-
morphisms are shown in Table 5. A G-to-A transition in the
promoter region (308) of the TNF-a gene results in higher
expression of TNF-a in vitro and in vivo [7]. TNF-a high-
expression allele increases the risk of oral cancer [7].
TNF-a is a proinflammatory multifunctional cytokine pro-
duced by macrophages. It plays an important role in the
regulation of immune response, because its increase after
traumatic injury generates a cytokine cascade resulting in
activation, proliferation, and hypertrophy of mononuclear
and phagocytic cells. TNF-a-initiated signaling pathways
activate proinflammatory gene expression via the tran-
scription factor nuclear factor-kappa B. TNF-a has been
implicated in the pathogenesis and progression of various
malignancies. In comparison to healthy individuals,
increased serum levels of TNF-a have been observed in
European patients with oral cancer [8]. Significantly higher
levels of salivary IL-6 and TNF-a were found in patients with
oral leukoplakia when compared with healthy controls [9].
SNPs in inflammation genes have been shown to alter their
expression and functions. TNF-a and IFN-g polymorphisms
contribute to susceptibility to oral lichen planus [10]. A
high-producing G/A genotype of TNF-a at position 308 was
more commonly found among the OPL patients of this
study.
IL-6 is an anti-inflammatory cytokine [11]. It has already
been well discussed that cigarette smoking affects the
Table 5 Cytokine gene polymorphisms and their associated phenotypes.
Cytokine gene polymorphisms Patients,
n (%)
Controls,
n (%)
p Adjusted OR
(95% CI)
p*
TNF-a (308)a
High G/A, A/A 29 (72.5) 48 (42.1) <0.001* 3.63 (1.65e7.97) <0.001
Low G/G 11 (27.5) 66 (57.9) 1
TGF-b1 (codon 10e25)
High T/T-G/G, T/C-G/G 23 (54.8) 113 (88.3) <0.001* 1
Intermediate/low (T/C-G/C, C/C-G/G,
T/T-G/C)/(C/C-G/C, C/C-C/C,
T/T-C/C, T/C-C/C)
19 (45.2) 15 (11.7) 13.40 (3.81e56.66) <0.001
IL-10 (1082, 819, 592)b
High/intermediate (GCC/GCC)/(GCC/ACC, GCC/ATA,
GCC/ATC)
4 (11.8) 16 (14.3) n.s.
Low ACC/ACC, ACC/ATA, ATA/ATA,
ATC/ATA
30 (88.2) 96 (85.7)
IL-6 (174)a
High G/G, G/C 35 (87.5) 104 (96.3) n.s. (0.062)
Low C/C 5 (12.5) 4 (3.7)
IFN-g (þ874)c
High T/T 0 (0.0) 5 (4.1) n.s.
Intermediate T/A 11 (28.2) 35 (28.9)
Low A/A 28 (71.8) 81 (66.9)
* Statistically significant difference between patients and control individuals (p < 0.05).
CI Z confidence interval; IFN Z interferon; IL Z interleukin; n.s. Z not statistically significant (p > 0.05); OR Z odds ratio;
TGF Z transforming growth factor; TNF Z tumor necrosis factor.
a Due to some technical problems the genotyping results of 40 patients were included.
b Due to some technical problems, the genotyping results of 34 patients were included.
c Due to some technical problems, the genotyping results of 39 patients were included.
556 H.-J. Hsu et al.immune system [12]. Cigarette smoking decreases bioactive
IL-6 secretion by alveolar macrophages. Betel quid compo-
nent also influences inflammatory reaction. Areca nut
extract induces IL-6 production by gingival keratinocyte and
also induces Cox-2 and IL-6 mRNA expression [13]. Betel quid
chewing contributes to the pathogenesis of cancer and oral
submucousfibrosis by impairingTcell activation and inducing
IL-6 production, which affect oral mucosal inflammation and
growth of oral fibroblast and oral epithelial cells [14].
IL-6 activates mainly the JAK1/STAT3 signal pathway and
functions as a proinflammatory factor [15]. Expression rates
of IL-6R and IL-6 mRNA transcripts in tumor specimens were
much higher than those in nontumor mucosa [16]. A G/C
SNP in the promoter region (174) of IL-6 was shown to
affect transcription and alter plasma IL-6 levels. As re-
ported in the literature, the IL-6 variant genotype (C/C)
frequency varied dramatically among different ethnic
groups; for example, it is very low in Asian populations [17].
Our control frequency, compared with other studies about
Southern Chinese population [18], is slightly higher. The IL-
6 polymorphisms have been linked to various malignancies
such as gastric, hepatocellular, lung, colorectal, cervical,
breast [19e21], and bladder cancers [22]. Significantly
higher levels of salivary IL-6 were found in patients with
oral leukoplakia when compared to healthy controls [9]. In
this study, we found an association between the variant C
allele of the 174 G > C SNP in the IL-6 promoter region
with an increasing OPL risk.
TGF-b1 induces tumor regression in vivo by Smad4-
independent pathways that sensitize keratinocytes tomitochondrial-mediated apoptosis [23]. TGF-b1 gene is
located on chromosome 19q13. SNPs in cytokine genes may
influence the expression or function of cytokines via cytokine
network, and many have been evaluated for their role in
inflammatory diseases and cancer predisposition. Two poly-
morphisms of TGF-b1 are located on codon 10
(869T > C::Leu/Pro) and codon 25 (915 G > C::Arg/Pro) of
exon 1 that encodes leader sequence of the protein and have
functional importance in modulating its transmembrane
transport. TGF-b1 low-production genotypes (TGF-b1 codon
10 CC) were associated with not only an increased risk of
breast cancer [24], but also an increasedoddof breast cancer
relapse and reduced 5-year disease-free survival rate [25].
The present study revealed that the codon 10 genotype is not
a critical factor in the development of OPL. Codon 25 of TGF-
b1 increased serum levels of TGF-b1 in the presence of the G
allele, which might contribute to long-term suppression of
epithelium proliferation, leading to a decrease in the risk of
OPL. The C allele at codon 25 may contribute to weaker
suppression of the epithelium proliferation, thereby
increasing the risk of OPL. TGF-b1 codon 25, not codon 10, is
an important risk factor of OPL, as found in the study. TGF-b1
is the major cytokine responsible for the regulation of
fibroblast proliferation and differentiation [26]. The rough
fibers present in betel nuts may cause multiple invisible tiny
abrasive wounds during betel quid chewing. Wound healing
was affected by the chemical component, which may
modulate cytokine secretion.
Polymorphism analysis of IFN-g, an important cytokine in
antitumor host defense, showed no genotype difference at
Polymorphisms of cytokine gene and risk of OPL 557position þ874 in OPL patients and controls. However, the
higher-producer T/T genotype at position þ874 was re-
ported to be significantly higher in hepatocellular carci-
noma in Brazil [27].
IL-10 is a multifunctional cytokine with both immuno-
suppressive and antiangiogenic functions, and consequently
has both tumor-promoting and tumor-inhibiting properties
[28]. Raised levels of serumand peritumoral IL-10 production
have been reported in many malignancies, which have been
interpreted in support of a role for IL-10 in tumor escape from
the immune response [29]. The IL-10 SNP and haplotype have
been reported to be associated with differential IL-10
expression in vitro, with the 1082 A, 819 T, and 592 A
haplotypes being associated with a decreased IL-10 expres-
sion, compared with the 1082 G, 819 C, and 592 C hap-
lotypes. SNPs at position 1082 A/G in the IL-10 gene
promoter are significantly associated with the risk of oral
cancer [30]. However, it has not been found to be associated
with OPL in our study.
Limitations of the present study need to be addressed. It
has been suggested that the sample size is always an
important issue. Statistical power of the analysis would
generally increase with increasing size of sample. Because
of the relatively small sample size, this study may not be
powerful enough to test the interaction among genes with
low frequencies.
This study provides evidence for the association be-
tween the variants IL-6, TNF-a (308), and TGF-b1 codon
10 genotype, and an overall increased OPL risk. While these
findings need to be replicated in larger, prospective
studies, they support the role of chronic inflammation as an
etiologic factor in this population.
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